Myriad Genetics, Inc. recently announced that Janssen Research & Development, LLC, will use Myriad’s BRACAnalysis test in connection with its Phase 3 clinical trial of Yondelis® (trabectedin) in the treatment of advanced-relapsed epithelial ovarian, primary peritoneal or fallopian tube cancers.
New Advances in Treating Hyperpigmentation
This past decade has seen an enormous surge in popularity of skin brightening products formulated specifically to treat hyperpigmentation and…

0 Comments